Schifferli J A, Ng Y C, Estreicher J, Walport M J
Department of Medicine, Hammersmith Hospital, London, United Kingdom.
J Immunol. 1988 Feb 1;140(3):899-904.
The role of complement and its receptor on erythrocytes (CR1) in the physiologic elimination of large immune complexes from the circulation of humans was assessed. Large radiolabeled soluble tetanus toxoid- anti-tetanus toxoid complexes were injected i.v. into three normal individuals and three patients with SLE. These complexes were prepared in antibody excess and were 45S in size, fixed C and bound to E CR1 in vitro. The percentage of complexes bound in vitro was directly proportional to CR1 number/E in four normal subjects and three SLE patients. After i.v. injection into normal subjects, complexes were cleared rapidly, with a monoexponential rate constant (10.3 to 11% complexes cleared/min). In the SLE patients, clearance was best explained by two phases: the first occurred within the first minute indicating immediate trapping of a fraction of the complexes (19.5 to 25.3% of injected complexes trapped), the second was monoexponential and was similar to the normal range. A large fraction of complexes bound within the first minute to E in vivo; the percentage of binding was variable, ranging from 16.3% to 71.5% and was related to E CR1 number. In a second study complexes were injected that had been attached to autologous E by opsonization with C in vitro. Their elimination was similarly monoexponential, except in one SLE patient in whom there was significant initial trapping (30.9%). A fraction of these complexes were released from E within the first minute, the percentage release being greatest in the patient with the lowest CR1 number (81.4%). E bearing immune complexes remained in the circulation and were not transiently sequestered in the liver or spleen. This is the first study of the clearance of soluble immune complexes in vivo in humans and shows that C and CR1 on E participate in immune complex clearance reactions, and that abnormal clearance can be detected in the form of rapid removal of immune complexes from the circulation.
评估了补体及其在红细胞上的受体(CR1)在人体循环中生理性清除大型免疫复合物的作用。将大型放射性标记的可溶性破伤风类毒素-抗破伤风类毒素复合物静脉注射到三名正常个体和三名系统性红斑狼疮(SLE)患者体内。这些复合物是在抗体过量的情况下制备的,大小为45S,在体外固定有补体并与红细胞CR1结合。在四名正常受试者和三名SLE患者中,体外结合的复合物百分比与红细胞CR1数量直接成正比。静脉注射到正常受试者体内后,复合物迅速清除,呈单指数速率常数(每分钟清除10.3%至11%的复合物)。在SLE患者中,清除情况最好用两个阶段来解释:第一阶段发生在第一分钟内,表明一部分复合物立即被捕获(捕获的注射复合物的19.5%至25.3%),第二阶段是单指数的,与正常范围相似。很大一部分复合物在第一分钟内在体内与红细胞结合;结合百分比各不相同,范围从16.3%到71.5%,且与红细胞CR1数量有关。在第二项研究中,注射了通过体外补体调理作用附着于自体红细胞的复合物。它们的清除同样呈单指数,除了一名SLE患者有显著的初始捕获(30.9%)。这些复合物中的一部分在第一分钟内从红细胞中释放出来,释放百分比在CR1数量最低的患者中最大(81.4%)。带有免疫复合物的红细胞留在循环中,不会暂时滞留在肝脏或脾脏中。这是首次对人体体内可溶性免疫复合物清除进行的研究,表明红细胞上的补体和CR1参与免疫复合物清除反应,并且可以通过免疫复合物从循环中快速清除的形式检测到异常清除。